Skip to main content

Table 2 Patient cohorts by country with duration of IVA exposure

From: Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

Country Overall G551D/IVA patient group F508del/SOC patient group
All countries, N 209 72a 137
 IVA exposure, mean (SD), months NA 21.8 (15.1) NA
France, n (%) 61 (29.2) 10 (13.9) 51 (37.2)
 IVA exposure, mean (SD), months NA 15.9 (8.4) NA
United Kingdom, n (%) 54 (25.8) 33 (45.8) 21 (15.3)
 IVA exposure, mean (SD), months NA 18.1b (11.4) NA
Germany, n (%) 47 (22.5) 14 (19.4) 33 (24.1)
 IVA exposure, mean (SD), months NA 19.6 (9.6) NA
Australia, n (%) 38 (18.2) 12 (16.7) 26 (19.0)
 IVA exposure, mean (SD), months NA 35.6 (24.1) NA
Ireland, n (%) 9 (4.3) 3 (4.2) 6 (4.4)
 IVA exposure, mean (SD), months NA 30.0 (0.0) NA
  1. IVA Ivacaftor, NA Not applicable, SD Standard deviation, SOC Standard of care
  2. aDuration on ivacaftor exposure was missing for 6 patients
  3. bn = 27